Nevertheless, considering the universal presence of PDK4 in both normal cells and tumor cells as well as the unsatisfactory pharmacokinetic features of DCA, new nanoformulation strategies are still urgently needed for enhancing the tumor‐targeted delivery of DCA. Here, PDK4 is linked to neoplasm.